The new CEO at Biogen Idec, George Scangos, just won a key vote of confidence from one of the prickliest investors on Wall Street. For the first time in four years Carl Icahn isn't trying to wrest control of the company with a new slate of rebel directors. And Alexander Denner, a managing director of Icahn Partners LP, tells the Wall Street Journal's Health Blog that "the company has obviously made significant progress" under Scangos. Since coming on board last year Scangos has instituted a blizzard of changes aimed at restructuring the company. And investors have responded positively, driving up shares by 22 percent. If there's one thing that Icahn can quickly warm up to it is a steadily rising stock. Report